Global Consensus Position Statement on the Use of Testosterone Therapy for Women

Susan R. Davis; Rodney Baber; Nicholas Panay; Johannes Bitzer; Sonia Cerdas Perez; Rakibul M. Islam; Andrew M. Kaunitz; Sheryl A. Kingsberg; Irene Lambrinoudaki; James Liu; Sharon J. Parish; JoAnn Pinkerton; Janice Rymer; James A. Simon; Linda Vignozzi; Margaret E. Wierman


J Clin Endocrinol Metab. 2019;104(10):4660-4666. 

In This Article


A Task Force of representatives of leading societies, whose international memberships includes clinicians assessing and managing sex steroid therapy for women, was established. The Task Force agreed on the issues that needed to be addressed after which a systematic review and meta-analysis of the benefits and risks of testosterone therapy for women was conducted.[1] The Task Force then met on 17th May 2019 in Berlin, Germany and drafted this consensus position statement.

Recommendations regarding the benefits and risks of testosterone therapy are based on findings from blinded placebo/comparator RCTs, of at least 12 weeks duration for which data were available for inclusion in meta-analyses.[1] The findings are reported with Levels of evidence and Grades of Recommendations.[2] Clinical practice recommendations are agreed expert opinions of the panel. Through constructive discussion, unanimous consensus agreement was reached on all the Expert Opinion recommendations included here.